Over 700 Alnylam Employees Volunteer at the Company’s 4th Annual “Helping Hands” Community Service Day

Jun 12,2018

Alnylam Supports 23 Local Organizations in the Greater Boston Area and Western Europe

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 12, 2018-- Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today kicked off its fourth annual company-wide “Helping Hands” Community Service Day benefiting 23 organizations, including 16 organizations in the Greater Boston area and seven organizations in Western Europe.

The program has successfully reached its fourth year and has expanded to more than 700 employees at 23 sites, dedicating 3,500 hours to local causes and organizations, a 150 percent increase from its inaugural year.

“Every summer we look forward to our ‘Helping Hands’ Community Service Day. This day provides the opportunity to not only give back to the community, but to support and connect with the important missions these organizations are striving to achieve. This day is an annual reminder that ‘Commitment to People’ is one of our core values at Alnylam,” said John Maraganore, Ph.D., Chief Executive Officer at Alnylam. “The enthusiasm and excitement our team members share leading up to and on ‘Helping Hands’ day is infectious, and we are extremely grateful to the organizations who continue to welcome us back year after year.”

Activities range from supporting underserved youth, restoration of parks, home ownership for low income families, fighting hunger, and other neighborhood initiatives. Beneficiary organizations include:

Nature Centers

Food Pantries and Meal Services

Childcare and Community Programs

The Company’s employees in Milan, Italy will hold their Community Service Day on June 29th. In addition, employees in Maidenhead, UK; Zug, Switzerland; Paris, France; Munich, Germany; Amsterdam, Netherlands; and Stockholm, Sweden will volunteer at local organizations on July 4th.

About Alnylam Pharmaceuticals

Alnylam (Nasdaq: ALNY) is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, and hepatic infectious diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust discovery platform and deep pipeline of investigational medicines, including four product candidates that are in late-stage development. Looking forward, Alnylam will continue to execute on its "Alnylam 2020" strategy of building a multi-product, commercial-stage biopharmaceutical company with a sustainable pipeline of RNAi-based medicines to address the needs of patients who have limited or inadequate treatment options. Alnylam employs over 800 people in the U.S. and Europe and is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit and engage with us on Twitter at @Alnylam or on LinkedIn.

Source: Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc.
Christine Regan Lindenboom, 617-682-4340
(Investors and Media)